# Viking Therapeutics

Type: Company (VKTX)

Source: GetYourBrief — https://getyourbrief.com/entity/viking-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/viking-therapeutics

## Timeline

- **2026-07**: Vertex announces $10 billion acquisition of Crinetics — Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed.

## Recent coverage (2 stories, network-wide)

### VKTX Stock: The $10B Vertex-Crinetics Deal Warms Up a $20B Viking Takeover
2026-07-31 06:15:41 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup.
Full story: https://getfinancebrief.com/story/viking-therapeutics-stock-vertex-crinetics-acquisition-finance

### Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?
2026-07-31 06:14:04 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Full story: https://getbiobrief.com/story/viking-therapeutics-vertex-crinetics-obesity-acquisition-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.